⌘K
t
Scancell Holdings plc announced on April 12, 2022, that Vulpes Life Science Fund, a substantial shareholder, had its 117,479,029 ordinary shares, representing 14.41% of the Company's issued share capital, transferred from its nominee, Barclays Bank PLC, to a new registered holder. The ultimate beneficial holder, Vulpes Life Science Fund, remains unchanged, and Barclays Bank Plc's total voting rights in Scancell became 0% as of March 30, 2022, following this transfer.
| Date | 12 Apr 2022 |
| Time | 15:47:24 |
| Category | Holding(s) in company |
| ID | 1657I |
Scancell Holdings plc
("Scancell" or the "Company")
Change of Registered Holder of Shares
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that it has been informed by Vulpes Life Science Fund, a Substantial Shareholder in the Company with 117,479,029 ordinary shares representing approximately 14.41% of the issued share capital of the Company (the "Vulpes Shares"), that their nominee, Barclays Bank PLC ("Barclays") being the registered holder, has transferred the Vulpes Shares to a new nominee and registered holder. The ultimate beneficial holder of these shares, Vulpes Life Science Fund, remains the same.
Barclays' TR-1: form for notification of major holdings is provided below.
|
For further information, please contact: |
|
|
|
|
|
|
|
|
|
Scancell Holdings plc |
+44 (0) 20 3727 1000 |
||
|
Dr John Chiplin, Executive Chairman |
|
||
|
Professor Lindy Durrant, CEO |
|
||
|
|
|
||
|
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) |
+44 (0) 20 7886 2500 |
||
|
Freddy Crossley / Emma Earl (Corporate Finance) |
|
||
|
Rupert Dearden (Corporate Broking) |
|
||
|
|
|
||
|
Stifel Nicolaus Europe Limited (Joint Broker) |
+44 (0) 20 7710 7600 |
||
|
Nicholas Moore / Samira Essebiyea / William Palmer-Brown (Healthcare Investment Banking) |
|
||
|
Nick Adams / Nick Harland (Corporate Broking) |
|
||
|
|
|
||
|
FTI Consulting |
+44 (0) 20 3727 1000 |
||
|
Simon Conway / Rob Winder / Alex Davis |
|
||
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope ® and ImmunoBody ® for vaccines and GlyMab™ and AvidiMab ® for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope ® and ImmunoBody ® ) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab™) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab ® ).
For further information about Scancell, please visit: https://www.scancell.co.uk/
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00B63D3314
Issuer Name
SCANCELL HOLDINGS PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of financial instruments
3. Details of person subject to the notification obligation
Name
Barclays Bank Plc
City of registered office (if applicable)
London
Country of registered office (if applicable)
United Kingdom
4. Details of the shareholder
|
Name |
City of registered office |
Country of registered office |
|
Barclays Capital Securities Ltd |
London |
United Kingdom |
5. Date on which the threshold was crossed or reached
30-Mar-2022
6. Date on which Issuer notified
01-Apr-2022
7. Total positions of person(s) subject to the notification obligation
|
|
% of voting rights attached to shares (total of 8.A) |
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) |
Total number of voting rights held in issuer |
|
Resulting situation on the date on which threshold was crossed or reached |
0.000000 |
0.000000 |
0.000000 |
0 |
|
Position of previous notification (if applicable) |
0.000000 |
14.441400 |
14.441400 |
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible) |
Number of direct voting rights (DTR5.1) |
Number of indirect voting rights (DTR5.2.1) |
% of direct voting rights (DTR5.1) |
% of indirect voting rights (DTR5.2.1) |
|
|
|
|
|
|
|
Sub Total 8.A |
|
|
||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Number of voting rights that may be acquired if the instrument is exercised/converted |
% of voting rights |
|
Collateral - Right to Recall |
|
|
0 |
0.000000 |
|
Sub Total 8.B1 |
|
0 |
0.000000% |
|
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Physical or cash settlement |
Number of voting rights |
% of voting rights |
|
|
|
|
|
|
|
|
Sub Total 8.B2 |
|
|
|
||
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
|
Ultimate controlling person |
Name of controlled undertaking |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
|
Barclays Plc |
Barclays Bank Plc |
|
|
|
|
Barclays Bank Plc |
Barclays Capital Securities Ltd |
|
|
|
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
To give you some background of the transaction here, Barclays Capital Securities Ltd ("BCSL"), a subsidiary wholly owned by Barclays Bank Plc ("BBPlc") has crossed the threshold of 10% of the Outstanding ISC ( Issued Share Cap) of the issuer in the usual framework of Business activity. BCSL holds these positions due to buy transactions carried out by a client who themselves happen to be in the "Prime Brokerage" business. These shares were then re-hypothecated from the client within BCSL and pledged with Bank of New York Mellon ("Tri-party agent") for onward financing. BCSL is able to recall these shares at any time.
Following our discussions held with business managers and compliance team , in this instance the Prime Brokerage client of BCSL is itself a financing intermediary, providing Prime Brokerage services to their underlying clients, and using BCSL as one of their service providers. As such, BCSL does not have any visibility over the ultimate economic owner/s of the shares being re-hypothecated from its client. Therefore, though we are not in a position to confirm the intent or otherwise of our client to continue accruing positions in this Issuer, Barclays has the right to choose to not finance any further additional positions.
Given the magnitude of the position, once it had been identified, the BCSL Prime Brokerage team contacted the client to request that they onward transfer the full position into a custody account away from Barclays. As the client's operations are primarily based in Singapore, the time difference meant this onward trade was only input subsequent to BCSL needing to satisfy its disclosure requirement. Following this transfer having now been booked, BCSL's position in this security is back to Zero(as of March 30th ) and we will be making an updated disclosure to this effect shortly.
12. Date of Completion
01-Apr-2022
13. Place Of Completion
London